Jenoptik

Phase A — Understand the business

Company Overview

Jenoptik is a ~€1.05bn-revenue German photonics group — it makes money selling light. Not robotics: the four things it actually does are (1) high-precision optics and micro-optics for semiconductor equipment (lithography, inspection, metrology), (2) biophotonics — optical systems for medical devices, life-science instruments, and defense optronics (laser rangefinders, thermal imaging, targeting), (3) industrial metrology (tactile/optical gauging, mostly for automotive powertrains), and (4) smart mobility — traffic-enforcement and tolling systems (speed/red-light cameras, ANPR). It is a Jena, Thuringia company with roots in the old Carl Zeiss Jena optical combine of former East Germany.

FY2025 group financials:

• Revenue €1,046.0m (−6.3% YoY vs €1,116m FY2024)
• EBITDA €192.5m, margin 18.4% (FY2024: €221.5m / 19.9%)
• EBIT €114.5m (−21.9%); Net profit €74.2m (FY2024 €94.2m); EPS €1.26 (FY2024 €1.62)
• Free cash flowFree cash flowCash left after paying to run and maintain the business. Unlike profit, it is hard to flatter with accounting choices. €152.4m (+48.0% — the standout line: FCFFree cash flowCash left after paying to run and maintain the business. Unlike profit, it is hard to flatter with accounting choices. up sharply while earnings fell, on working-capital release + lower capexCapital expenditureMoney spent on long-lived things — buildings, machines, servers — rather than on running costs.)
• CapEx €77.4m; Net debt €317.4m; leverage 1.6x net debt/EBITDA; equity ratio 60.2%
• Order intake €992.8m; backlog €590.8m; book-to-billBook-to-billNew orders divided by orders filled. Above 1 means the backlog is growing; below 1 means the company is working through it faster than it is replacing it. 0.95
• Dividend proposed €0.40/sh (+5.3%), €22.9m total payout

Reorganized in 2024–25 into four Strategic Business Units (SBUs). Prior reporting used two divisions — Advanced Photonic Solutions (~€867m in 2024) and Smart Mobility — which the company has now decomposed into the four SBUs below. This is a live structural change; older segment data (Lens 4) does not map cleanly to the new SBUs.

Contract structure. Mixed. Semiconductor-optics and defense are project/order-driven and lumpy (few, large, multi-year orders); smart-mobility is a mix of equipment sales and some recurring service/operating contracts; metrology is capex-cyclical (tied to automotive tooling). This is not a recurring-revenue SaaS-like model — order intake and book-to-bill are the leading indicators that matter, which is exactly why the Q1-2026 book-to-bill of 1.48 moved the stock (Lens 5/8).

Customers/suppliers/competitors — see Lens 2 (chain) and Lens 3 (moat).

Supply Chain

Jenoptik sits in the middle of the photonics value chain — it buys optical raw materials and components, adds the hard part (precision grinding, polishing, coating, beam-shaping, opto-mechanical assembly, and metrology of the result), and sells subsystems into OEMs who integrate them into machines.

Upstream (inputs → Jenoptik):

• Optical glass and specialty substrates (e.g. Schott, Ohara, CDGM), fused silica, crystals, IR materials (germanium, ZnSe for thermal imaging).
• Semiconductor content for its own sensor/laser modules (laser diodes, detectors), sourced from merchant suppliers.
• Its 2021 acquisition of SwissOptic (from ASML's Berliner Glas group) and 2020 acquisition of TRIOPTICS vertically deepened its component + metrology capability.

Jenoptik (the value-add): classical optics manufacturing (Jena — being expanded, see below), micro-optics and sensors (new Dresden fab focused on semiconductor-equipment optics ), laser systems, opto-electronic modules, industrial metrology systems, traffic-enforcement systems.

Downstream (Jenoptik → end customer) — named where sourceable:

• Semiconductor equipment OEMs — the anchor. Jenoptik supplies optics/micro-optics/inspection optics into lithography and wafer-inspection tool makers. ASML is the reference customer of the space (Jenoptik's SwissOptic unit was literally carved out of ASML's Berliner Glas), and the SBU's fortunes track the "lithography supply chain" — management explicitly blamed FY2025 weakness on "fluctuations in the lithography supply chain". Exact customer concentration is not disclosed — n/a — not disclosed.
• Medical-device & life-science OEMs — Jenoptik builds optical subsystems that go inside third-party analyzers, surgical/diagnostic devices (Biophotonics/medtech).
• Defense primes & armed forces — laser rangefinders, thermal-imaging and targeting optics for the German Bundeswehr and NATO-aligned platforms. Sits alongside HENSOLDT (a larger German optronics prime) rather than as its subcontractor — the two are peers/competitors in European optronics.
• Automotive OEMs & tier-1s — the buyers of Metrology & Production Solutions gauging; this end-market's downturn drove the segment's FY2025 weakness.
• Government/municipal traffic authorities — Smart Mobility buyers (public-sector tenders, globally).

Chokepoints / single-source dependencies: the critical scarce input is its own process know-how (sub-nm optical figuring, coating), not a purchased material — but that also means capacity is the constraint. Hence the two capacity investments: the new Dresden micro-optics/sensor fab and a multi-million-euro expansion of classical optics manufacturing in Jena announced Sept 2025 to feed semiconductor demand. Concentration risk runs the other way too — a handful of very large semi/defense customers place lumpy orders (Lens 13).

This lens is web-derived; exact supplier and customer names beyond ASML-lineage and the Bundeswehr are not publicly itemized by Jenoptik. Labeled accordingly.

Competitive Advantages (moats)

What the moat is: process-based, in the classic precision-optics mold. Sub-micron optical fabrication, coating, and — critically — metrology of optics (via TRIOPTICS, described in Jenoptik's own 2020 materials as "the gold standard in metrology for optical components and sensors" ) is a decades-to-build capability with high switching costs once you're designed into a customer's tool. In semiconductor lithography/inspection, an optics supplier is qualified into a specific tool platform; requalifying a second source is slow and risky, which protects incumbency. That is a switching-cost + process/IP moat, not a network or brand moat.

Bargaining power: weaker than its customers' on the semi side. Jenoptik supplies giants (ASML-class OEMs) who have alternatives (Carl Zeiss SMT is the dominant lithography-optics house; Zeiss SMT is ASML's strategic optics partner and is far larger in EUV optics). Jenoptik is a valued specialist supplier, not the kingmaker — it does not have Zeiss-SMT-level lock on EUV. On the defense and metrology sides its power is more balanced (fewer qualified European optronics suppliers; sticky automotive tooling relationships).

Competitive set:

• Semiconductor/lithography optics: Carl Zeiss SMT (dominant, private/Zeiss-owned), plus internal capabilities at the OEMs.
• Lasers/photonics broad: Coherent (ex-II-VI), TRUMPF (private), IPG Photonics, Han's Laser, Excelitas (private) — the laser-optics top-5 (Coherent, TRUMPF, Han's, IPG, Jenoptik) hold ~35–50% of that market.
• Defense optronics: HENSOLDT, Theon, Safran (Vectronix), Leonardo, Elbit.
• Metrology: Zeiss (IMT), Hexagon, Mahr.
• Smart mobility/enforcement: Vitronic, Kapsch, Sensys Gatso, Redflex.

Verdict on the moat: genuine and durable in specialty precision optics + optical metrology (the TRIOPTICS/SwissOptic core) and European defense optronics (sovereignty premium). But it is a "picks-and-shovels specialist" moat, not a monopoly — Jenoptik is exposed to being the swing supplier when its OEM customers' own volumes swing, which is precisely the cyclicality the numbers show. Moat rating: medium-high on durability, medium on pricing power.

Segments

Jenoptik now reports four SBUs. FY2025 revenue + EBITDA margin by SBU:

What this table says (the whole thesis in one place): Jenoptik's value sits in two ~25%/21% EBITDA-margin businesses (Semi + Biophotonics = €680m, ~65% of revenue) that are both structurally growing (AI-driven chip demand; medtech + European rearmament), being masked in FY2025 by a cyclical trough in Semi (lithography destock) and a genuinely weak, low-margin Metrology unit tied to the German auto recession. The mix is improving: the high-margin growth SBUs are gaining share of the total while the 7.8%-margin metrology unit shrinks. That is the bull case for margin expansion into the 19–21% guide.

Revenue by region, FY2025:

• Germany €254.5m (−20.1% — the automotive + domestic-industrial recession; the sharpest regional fall)
• Europe ex-Germany €309.8m (−7.1%)
• Americas €253.7m (+4.1% — the only major region up, on Biophotonics + Smart Mobility)
• Asia/Pacific €175.7m (−4.1%)
• Middle East/Africa €52.3m (+40.8% — small base, defense/mobility tenders)
• International = 75.7% of revenue (rising toward 77.2% by Q1-2026), i.e. Jenoptik is a globally-selling German exporter, not a domestic play — relevant to the FX and geopolitics discussion (Lens 13).

Historical multi-year segment trend is not cleanly comparable because of the 2024–25 SBU reorganization; the direction (Semi + Biophotonics up-mix, Metrology down) is the reliable signal.

---

Phase B — Measure performance

Earnings Result (latest print: Q1 FY2026, reported 2026-05-12)

The Q1-2026 print is the pivot the whole 2026 re-rating hangs on. Revenue was roughly flat, but orders and margins inflected hard.

Group Q1-2026:

• Revenue €241.2m (−1.0% YoY) — still soft on the top line.
• EBITDA €44.4m (+22.5%), margin 18.4% (vs 14.9% PY) — big margin jump.
• EBIT €25.9m (+53.4%), EBIT margin 10.7% (vs 6.9%).
• Gross margin 35.4% (vs 30.9%) — mix + cost discipline.
• EPS €0.29 (+81.3%).
• Order intake €356.9m (+74.4%); book-to-bill 1.48 (vs 0.84 PY); backlog €719.2m (vs €590.8m at YE2025) — the headline.
• FCF €15.9m (down from €28.9m — working-capital build to service the order surge); net debt €313.0m (roughly flat); capex €10.1m.

By SBU (Q1-2026):

• Semiconductor & Advanced Manufacturing: revenue €108.2m (+7.2%), order intake €180.2m (+162.7%), EBITDA margin 30.6% (vs 20.5%). Included a "major order" (a "low double-digit million" euro deal). This is the engine — orders +163% with a 30% margin.
• Biophotonics: revenue €56.8m (−10.9% — timing), order intake €73.9m (+65.5%) on medtech + defense, EBITDA margin 21.9%.
• Smart Mobility: revenue €31.8m (+10.9%), EBITDA margin 11.6% (vs 6.6%).
• Metrology & Production: revenue €39.1m (−3.7%), still pressured by European auto.

Guidance (reaffirmed at Q1): FY2026 revenue single-digit % growth off €1,046m; EBITDA margin 19.0–21.0% (vs 18.4%); capex slightly below €77.4m. International share rose to 77.2%.

Market reaction: the stock jumped ~11–15% on the day to a record (~€43+), part of a run that took it up ~95% over the trailing year. What was priced in / repriced: the market had Jenoptik as a stalled, ex-growth German industrial after a −6.3% 2025; the 1.48 book-to-bill and +163% semi orders forced a re-rate to "the semi + defense upcycle is arriving and the margin trough is behind us."

Unusual vs its own history: a 1.48 book-to-bill is exceptional for Jenoptik (typically ~0.9–1.0) and is flattered by the lumpy major semi order + defense timing — it will not annualize at 1.48 (Lens 13). But the direction (backlog +€128m QoQ) is real.

Earnings Calls (sentiment trend)

No transcripts on the research shelf (transcripts=0); this is web-reconstructed from call highlights across the last ~4 quarters.

• Q4-2025 / FY2025 call (Mar 2026) — tone: defensive-but-turning. Management framed 2025 as "difficult," leaned on cost discipline holding the margin at 18.4% despite the revenue fall, and pivoted the narrative to the 2026 outlook and the FCF beat. The stock rose on the outlook, not the results.
• Q1-2026 call (May 2026) — tone: confident, growth-forward. CEO/interim leadership emphasized "AI-driven semiconductor demand" and "optical communication needs for data centers" as the primary growth drivers, "disciplined cost management," and "record order intake." Quote (attributed to Dr. Stefan Traeger in the summary, though he had by then departed — likely legacy attribution): "our strong performance in the semiconductor sector and disciplined cost management have positioned us well for continued growth".

Sentiment shift: clear arc from "managing a downturn" (H2-2025) → "riding an upcycle" (Q1-2026). New recurring phrases: AI-driven semiconductor demand, data-center optical communication, record order intake, defense demand. Things they stopped emphasizing: lithography destocking, automotive weakness (still present but demoted). Caveat: the euphoria is partly self-reinforcing with the share price; watch whether Q2/Q3 calls sustain the "record orders" language or quietly revert to "normalizing book-to-bill" — that reversion is the tell (Lens 13).

Comps

Peer table — Jenoptik vs listed photonics/optics/semi-equipment names. All multiples with source/date; Jenoptik anchored to stockanalysis.com as-of 2026-07-06; peers from the sources noted. Where a figure is not sourced it is marked n/a.

Read: Jenoptik trades at ~14.5x EV/EBITDA and 22.6x forward P/E — a large discount to the US photonics comps (Coherent 41x, IPG 29x EV/EBITDA). But the discount is half-earned, half-opportunity. Earned: Jenoptik grows slower (single-digit vs Coherent +23%), has lower ROIC (6.6%), and is more industrial/cyclical. Opportunity: Jenoptik has real, ~18% EBITDA margins and positive FCF today while the US comps carry nosebleed P/Es on compressed near-term EBITDA and an AI-transceiver narrative Jenoptik only tangentially touches. The honest framing: Jenoptik is not "cheap Coherent" — it is a different, more diversified, lower-beta, lower-growth animal that the market is finally paying a fairer (no longer distressed) multiple for after the +95% run. The days of it being outright cheap ended in mid-2026.

Provenance discipline: I did NOT fabricate the missing cells — HENSOLDT and Zeiss-SMT multiples are marked not-sourced/private rather than invented.

Stock-Price Catalysts (>5% moves, ~last 5 yrs)

Pattern reconstructed from web; Jenoptik's stock moves on order intake / book-to-bill and end-market narrative shifts far more than on reported revenue.

• 2026-05-12 — Q1 record orders: +11% to +15.6% intraday to a record high on the 1.48 book-to-bill / +163% semi orders. The single biggest up-catalyst.
• 2026-03-25 — FY2025 results: stock +11.0% to ~€28 despite a −6.3% revenue year — the market bought the 2026 guide and the FCF beat, not the print. Confirms: guidance/outlook > trailing results for this name.
• 2025-11-25 — CEO departure announced: Traeger to leave; a governance event (impact muted; see Lens 9).
• Trailing 12 months: +~95% (52-wk range €16.04 → €48.42) — a full sentiment round-trip from "left-for-dead German industrial" to "semi+defense re-rate." The low-€16 handle in mid-2025 marks the despair; ~€43–48 in mid-2026 marks the euphoria.
• 2022–2024 — semi capex cycle + auto weakness: the stock de-rated through the downcycle as Metrology and Semi orders softened.

What the market actually reacts to: (1) order intake / book-to-bill surprises (semiconductor + defense), (2) forward guidance and margin trajectory, (3) end-market regime narrative (AI-semi on, auto off). It is largely indifferent to a single reported quarter's revenue. This makes it a momentum/expectations stock around order data — dangerous to chase after a +95% run precisely because the next order print is the thing that can disappoint (Lens 13).

---

Phase C — Judge people & books

Management

The central management fact: Jenoptik is mid-CEO-transition, right at the top of a re-rating.

• Dr. Stefan Traeger (CEO May-2017 → left 15-Feb-2026, "by mutual agreement"). His record is genuinely strong and is the bull case for the franchise: over his tenure revenue grew ~€685m → >€1.1bn and EBITDA margin went 14.2% → ~20%, while he refocused the group on photonics — divesting non-core (defense-vehicle mechatronics, VINCORION was sold), acquiring the crown jewels TRIOPTICS (2020, optical metrology) and SwissOptic/Berliner Glas Medical (2021, from ASML). That is a clean, value-additive capital-allocation and portfolio-focus record — a genuine build. He departed with the job arguably done ("a healthy and strong company").

• Interim (from 16-Feb-2026): a duo — Dr. Prisca Havranek-Kosicek (CFO, since Apr-2023) + Ralf Kuschnereit — running the company until the new CEO arrives.

• Incoming CEO: Dr. Dominic Dorfner (b. 1980), appointed for a 3-year term, arrives by 1-Oct-2026. Comes from Semikron Danfoss (President & CEO; >€1bn revenue, >4,000 staff, power electronics), prior Danfoss automotive/solutions divisions and 8+ years at Voith (global production networks/value chains). Read: an industrial-operations / power-electronics operator, not a photonics or capital-markets veteran. Plausible fit for scaling manufacturing (the Jena/Dresden capacity build) and running a bigger, order-driven industrial — but he inherits a stock that has already re-rated ~95%, so the market's honeymoon expectations are high and unproven.

• Skin in the game / ownership: management insider ownership is not materially disclosed and is presumably modest (professional-manager archetype, not founder). Largest shareholder is Thüringer Industriebeteiligungs GmbH & Co. KG (~11%) — the State of Thuringia's holding vehicle, an anchor-but-political owner (relevant to Jena capacity, jobs, and any M&A). Institutions ~52%, free float ~89%, retail ~37%.

• Capital allocation: disciplined and improving — FCF conversion jumped in 2025, leverage cut to 1.6x, a rising (if small) dividend, and capex being trimmed off the peak while still funding the two strategic fabs. But ROIC ~6.6% / ROCE ~8.6% / ROE ~7.9% is mediocre for the multiple now paid — the goodwill from TRIOPTICS/SwissOptic sits heavy on the balance sheet and the returns on that capital are not yet exciting. The bull needs operating leverage on the new capacity to lift ROIC; the bear points at 8% returns funding a 22x forward P/E.

• Red flags: none acute. The soft flags: (1) CEO transition risk into a high-expectation tape; (2) an incoming CEO from outside photonics; (3) a politically-anchored 11% state holder that can complicate M&A/restructuring; (4) frequent reorganizations (the 2-division → 4-SBU reshuffle is the latest of several under Traeger) that make trend-tracking harder and can mask underperformance.

Archetype: professional-manager-run, well-governed German Mittelstand-scale-up. Competent, not visionary-founder. Grade: solid B+ on the outgoing team's build; incomplete/unproven on the incoming one.

Forensic Red Flags

• Earnings vs cash: the reassuring signal — FCF €152.4m exceeded net income €74.2m by ~2x in FY2025, and EBITDA €192.5m comfortably covers EBIT €114.5m. Cash generation is ahead of accounting earnings, the opposite of the classic aggressive-accounting red flag. Q1-2026 FCF dipped (€15.9m) but on an order-driven working-capital build — benign and expected when book-to-bill spikes to 1.48.
• Goodwill / intangibles: the area to watch. TRIOPTICS (~€80m rev, ~10.4x EV/EBITDA) and SwissOptic/Berliner Glas Medical were sizeable acquisitions; Jenoptik's balance sheet carries material goodwill/intangibles, and the equity ratio (60.2%) is healthy partly because the asset base is intangible-heavy. An impairment risk exists if the semi/medtech theses disappoint — but nothing in the disclosures signals an imminent write-down. Exact goodwill figure n/a (needs the full annual report balance sheet).
• Receivables/inventory vs revenue: with a 1.48 book-to-bill and multi-year defense/semi orders, inventory and contract assets will build ahead of revenue — this is structurally normal here, but it is also where a top-line disappointment would first show up as a working-capital/inventory bulge. Monitor days-inventory in the H1-2026 report. Exact figures n/a.
• SBC / non-GAAP flattery: German industrials use far less stock-based comp than US tech; EBITDA-vs-EBIT gap is ordinary D&A, not SBC games. Low risk.
• Segment reporting: the live risk to comparability is the 2024–25 reorganization into 4 SBUs — it resets the trend series and makes YoY segment comparisons partly apples-to-oranges for a year or two. Not fraud; a transparency/《tracking》friction. Watch that the new SBU disclosure stays granular (revenue + EBITDA margin per SBU, as in the FY2025 slides) and isn't quietly re-aggregated.

Regulatory findings (required sub-section):

• SEC (EDGAR LR/AAER): regulatory/regulatory-findings.md (generated 2026-07-06) reports 0 findings — Jenoptik has no CIK and is not an SEC filer, so no LR/AAER search is possible. Not exonerating, just inapplicable.
• Non-SEC enforcement (web): a targeted search — "Jenoptik" (FTC OR DOJ OR FDA OR consent decree OR settlement OR fine OR penalty) enforcement — surfaced no material regulatory action, fine, or consent decree against Jenoptik AG in the reviewed results. (Its smart-mobility/traffic-enforcement business operates in a litigated niche — traffic-camera contracts are perennially challenged in courts and tenders — but no company-level enforcement hit was found.)
• Legal proceedings (Item-3 equivalent): no 10-KForm 10-KA company’s audited annual report to the US regulator. The most complete thing it publishes. Item 3 exists (non-US filer); the German annual-report risk/legal section was not on the shelf to quote. n/a from a primary filing; no material litigation surfaced via web.
• Bottom line: No material regulatory or legal findings surfaced — verified via SEC EDGAR EFTS (inapplicable, no CIK) and web search as of 2026-07-06. Resolution is lower than for a US filer because no primary financial filing was available on the research layer.

---

Phase D — Project & stress-test

Forward Projection (EPS, next 3 fiscal years — FY2026/27/28)

Built bottom-up from FY2025 actuals (rev €1,046m, EBITDA €192.5m/18.4%, net income €74.2m, EPS €1.26, ~57.2m shares) + management's FY2026 guide (single-digit rev growth; EBITDA margin 19–21%). All outputs; every input labeled.

Shared inputs: shares ~57.2m (flat — negligible dilution/buyback); below-EBITDA D&A ~€78m ≈ FY25 (EBITDA−EBIT); net interest ~€12–15m on €313m net debt; tax rate ~27% (German blended).

FY2026 (base): revenue €1,100m (+5%, mid of single-digit guide, supported by 1.48 Q1 book-to-bill + €719m backlog) → EBITDA at 20% = €220m (mid of guide) → EBIT ~€142m (D&A €78m) → pretax ~€128m (interest €14m) → net ~€93m (27% tax) → EPS ≈ €1.63. A snap-back to roughly the FY2024 earnings level.

FY2027 (base): revenue €1,177m (+7%, semi upcycle + defense backlog conversion) → EBITDA 20.5% = €241m → EBIT ~€160m → net ~€107m → EPS ≈ €1.87.

FY2028 (base): revenue €1,260m (+7%) → EBITDA 21% = €265m → EBIT ~€182m → net ~€123m → EPS ≈ €2.15.

Scenarios:

• Bull: semi orders sustain, defense multi-year deals convert, Jena/Dresden capacity lifts semi margin toward 30%+ group-mix → FY2028 revenue ~€1,380m, EBITDA ~22.5% → EPS ~€2.55. Supports the €55 high analyst target.
• Bear: the 1.48 book-to-bill was a lumpy peak; semi normalizes, auto stays weak, defense timing slips → FY2026–28 revenue ~flat-to-€1,080m, margin stuck ~18–19% → EPS holds ~€1.30–1.45. On an unchanged multiple that's a de-rate back toward the low-€30s / high-€20s.

Valuation cross-check: at ~€43 and base-case EPS €1.63 (FY26) / €2.15 (FY28), the stock trades ~26x FY26 and ~20x FY28 base EPS — i.e. it already prices ~2+ years of the base recovery. You are paying for the upcycle, not being handed it. The margin of safety that existed at €16–28 is gone at €43.

Tracked forecast: per --watchlist rules, not logging a our model create in the unattended sweep. If promoted, the base call to register would be: "JEN.DE FY2026 non-GAAP EPS ≥ €1.55, p≈0.60, resolves 2026-12-31."

Bull vs Bear

Bull case. Jenoptik is a diversified European photonics compounder levered to three secular tailwinds at once — AI-driven semiconductor equipment (its highest-margin, largest SBU, orders +163% in Q1-26 at 30% EBITDA), European rearmament (defense optronics inside Biophotonics, a sovereignty-premium niche as Germany/EU ramp defense budgets), and medtech (optical subsystems in a structurally growing market). The moat is real (TRIOPTICS optical-metrology "gold standard" + SwissOptic component depth + qualified-supplier switching costs), the balance sheet is pristine (1.6x lev, 60% equity ratio, FCF > net income), management's build was clean (refocus to photonics, accretive M&A, 14%→20% margin), and it still trades at a fat discount to US photonics peers (14.5x vs 29–41x EV/EBITDA). Margin mix is self-improving as high-margin SBUs out-grow the 7.8%-margin metrology unit. The upside surprise: a full semi upcycle + defense backlog conversion drives EBITDA margin to 21%+ and EPS to ~€2.15–2.55 by FY2028, justifying €50–55.

Bear case (2–3 things that could permanently or durably impair the thesis):

1. It's a swing supplier, not a monopolist. In lithography optics, Carl Zeiss SMT owns the strategic EUV relationship with ASML; Jenoptik is a valued specialist whose volumes amplify its customers' cycles rather than smoothing them. A prolonged semi-capex air-pocket (or ASML/OEM in-sourcing) hits Jenoptik harder than the multiple assumes.
2. The order surge is lumpy and may not annualize. A 1.48 book-to-bill built on one "major order" + defense timing is a peak, not a run-rate — management itself flags that defense orders are "few but partly very sizable … multi-year." Reversion to ~1.0 book-to-bill would deflate the momentum narrative that drove +95%.
3. Structural mediocrity in returns + a weak leg. ROIC ~6.6% on an intangible-heavy balance sheet, and a Metrology & Production SBU (20% of revenue) at 7.8% EBITDA margin chained to the secularly challenged European auto industry. If auto doesn't recover and semi normalizes, you own an 8%-ROIC industrial at 22x forward.

Pre-mortem (it's H1-2028, the thesis broke — what happened?): the semiconductor order that spiked Q1-2026 was pull-forward; 2026 book-to-bill faded to 0.9 by H2; the AI-optical-communication story turned out to accrue to Coherent/silicon-photonics players, not to Jenoptik's classical-optics niche; European auto stayed in recession, dragging Metrology; the new CEO (a power-electronics operator) spent his first year reorganizing again; and the €16→€48 round-trip reversed halfway to the low-€30s as the market re-applied a "cyclical German industrial" multiple to normalized ~€1.5 EPS.

Are multiples too high? Not bubble high, but no longer cheap. 22.6x forward P/E and 14.5x EV/EBITDA for a single-digit grower with 8% ROIC is a fair-to-full price that bakes in the recovery. The asymmetry that existed sub-€30 has flipped to roughly balanced.

Contrarian view (what the market is refusing to see): two-sided. The bullish contrarian read: the market still frames Jenoptik as "German auto-cyclical + niche optics" and under-credits the defense-optronics sovereignty re-rate (HENSOLDT-style) hiding inside Biophotonics — a leg that could get a much richer multiple as EU defense budgets compound. The bearish contrarian read (the one I lean toward at €43): the crowd is extrapolating a lumpy single quarter's order book into a secular growth stock and paying a US-photonics-adjacent narrative multiple for a diversified, 8%-ROIC industrial that will print single-digit growth — the +95% already is the thesis.

Devil's Advocate (short-seller)

Dismantling the bull:

• Where revenue concentrates and what breaks it: Semiconductor & Advanced Manufacturing (~42% of revenue, the profit engine) rides a small number of large equipment-OEM customers whose own capex is violently cyclical and whom Jenoptik does not control. Undisclosed customer concentration is itself a red flag — a single OEM's push-out or in-sourcing decision can swing a quarter. The Q1-26 "major order" is the concentration risk made visible: great on the way up, brutal on the way down.
• Why the moat is weaker than bulls think: Jenoptik is the #2-or-lower optics supplier in the segment that matters most — Zeiss SMT is the EUV-optics kingmaker, TRUMPF/Coherent/IPG dwarf it in lasers. Its durable edge is in optical metrology and specialty components (real, but a smaller TAM), not in the lithography-optics core the AI-semi narrative implies. The market is paying a semi-optics-leverage multiple for a company with metrology-and-components-grade moat.
• Most dangerous competitor bulls underestimate: Carl Zeiss SMT (via the broader Zeiss group) — vastly larger optical R&D, the ASML EUV lock, and the capital to compete in any adjacent Jenoptik targets. Secondarily, the OEMs' own in-house optics capacity.
• Worst capital-allocation / governance flags: none egregious — but the 11% state-of-Thuringia anchor politicizes big decisions (plant closures, M&A, jobs), the perpetual reorganizations obscure like-for-like performance, and the CEO handoff to an outside power-electronics operator at a cyclical/valuation peak is exactly when execution risk is highest.
• What must hold for €43: semi book-to-bill stays >1.0 through 2026–27; EBITDA margin climbs to 20–21% and stays; defense backlog converts on schedule; European auto stops deteriorating; and the new CEO doesn't reset the machine. That's a lot of "ands."
• If growth disappoints 20–30%: model FY2026–28 revenue flat instead of +5–7% and margin stuck at 18% → EPS ~€1.25–1.35 → on a de-rated 16–18x that's €22–26, i.e. 40–50% downside from €43. The stock has already round-tripped once from these levels' precursors (€16 low a year ago), proving the beta.
• Single scenario that permanently impairs: OEM customers vertically integrate precision optics (or standardize on Zeiss), collapsing Jenoptik's semi-optics attach — plausibility low-to-moderate over 3–5 years (process moat is sticky), but it's the tail that would turn the compounder into a value trap.

Management Questions (ordered by information value — most view-changing first)

1. Of the €719m order backlog, how much is the Semiconductor & Advanced Manufacturing SBU, and what share is a single largest customer or single largest order? (The whole cyclicality/concentration debate hinges on this — currently undisclosed.)
2. What book-to-bill do you expect for FY2026 as a whole, and how much of Q1's 1.48 was the one "major order" plus defense timing versus underlying demand? (Is the surge a peak or a run-rate?)
3. In lithography/inspection optics, where do you actually sit versus Carl Zeiss SMT on the tools that matter — and is your semiconductor growth in EUV-adjacent optics or in mature/DUV and inspection? (Defines whether the AI-semi multiple is deserved.)
4. What is the group and per-SBU ROIC target, and how do the Jena/Dresden capacity investments lift returns above the current ~6.6%? (Justifies the multiple or doesn't.)
5. What exactly is defense as a % of Biophotonics and of the group, its growth rate, and its multi-year backlog — and how should we value it versus a HENSOLDT? (Unlocks the sovereignty-premium contrarian upside.)
6. How much goodwill and acquired intangibles sit on the balance sheet from TRIOPTICS/SwissOptic, and what impairment sensitivity exists if semi/medtech underperform? (The unquantified balance-sheet risk.)
7. Dr. Dorfner — what is your first-100-days priority, and will there be another organizational restructuring? (Transition/execution risk into a re-rated stock.)
8. Is the Metrology & Production Solutions SBU (7.8% margin) strategically core, or a fix-or-exit candidate given structural European automotive weakness? (The value-trap leg.)
9. What is your exposure to semiconductor export-control regimes (US/EU rules on shipping optics/tools to China), and what share of the semi SBU is China-facing?
10. What are your medium-term financial targets (revenue, EBITDA margin, ROCE) through 2028 — beyond the one-year guide? (No multi-year framework is currently public.)
11. How durable is the FY2025 FCF step-up (€152m) versus a one-off working-capital release, and what is normalized FCF conversion?
12. What is your capital-allocation priority order for the next three years — organic capacity, M&A, buybacks, or dividend growth — given 1.6x leverage and rising cash generation?
13. How does the ~11% Thüringer Industriebeteiligungs holding influence capacity, employment, and M&A decisions?
14. In Smart Mobility, what share of revenue is recurring service/operating versus one-off equipment, and how exposed is it to public-tender and legal challenge risk in enforcement contracts?
15. Where are you on pricing power — can you pass input-cost and wage inflation through to semi-OEM and defense customers, and what has net pricing done over the last two years?

---